<VariationArchive VariationID="2424522" VariationName="NC_000015.9:g.(?_89862161)_(89864158_?)del" VariationType="Deletion" Accession="VCV002424522" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1949600" VariationID="2424522">
      <GeneList>
        <Gene Symbol="POLG" FullName="DNA polymerase gamma, catalytic subunit" GeneID="5428" HGNC_ID="HGNC:9179" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89316320" stop="89334824" display_start="89316320" display_stop="89334824" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="89859535" stop="89878025" display_start="89859535" display_stop="89878025" Strand="-" />
          </Location>
          <OMIM>174763</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000015.9:g.(?_89862161)_(89864158_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>15q26.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" innerStart="89862161" innerStop="89864158" display_start="89862161" display_stop="89864158" variantLength="1998" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.(?_89862161)_(89864158_?)del" Assembly="GRCh37">
            <Expression>NC_000015.9:g.(?_89862161)_(89864158_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000015.9:g.(?_89862161)_(89864158_?)del AND Progressive sclerosing poliodystrophy" Accession="RCV003122608" Version="3">
        <ClassifiedConditionList TraitSetID="3716">
          <ClassifiedCondition DB="MedGen" ID="C0205710">Progressive sclerosing poliodystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-17" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18546365</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20142534</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20883824</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21880868</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25914719</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3716" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="105" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA depletion syndrome 4A (Alpers type)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA Depletion Syndrome 4A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers diffuse degeneration of cerebral gray matter with hepatic cirrhosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers progressive infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Poliodystrophia cerebri progressiva</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progressive cerebral poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Diffuse cerebral degeneration in infancy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neuronal degeneration of childhood with liver disease, progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive sclerosing poliodystrophy</ElementValue>
                <XRef ID="Progressive+sclerosing+poliodystrophy/9168" DB="Genetic Alliance" />
                <XRef ID="20415001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers-Huttenlocher Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PNDC</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">MTDPS4A</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5783" />
                <XRef ID="5783" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29517884</ID>
                <ID Source="BookShelf">NBK487393</ID>
              </Citation>
              <XRef ID="726" DB="Orphanet" />
              <XRef ID="C0205710" DB="MedGen" />
              <XRef ID="MONDO:0008758" DB="MONDO" />
              <XRef Type="MIM" ID="203700" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7073372" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_002693.2_15_Partial deletion (exons 18-20)_89862160_89864158|MedGen:C0205710" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003791183" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18546365</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20142534</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20883824</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21880868</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25914719</ID>
          </Citation>
          <Comment>This variant results in the deletion of exons 19-20 and part of exon 18 (c.2820_3273+1del) of the POLG gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in POLG are known to be pathogenic (PMID: 18546365). This variant has not been reported in the literature in individuals affected with POLG-related conditions. This variant disrupts a region of the POLG protein in which other variant(s) (p.Pro1073Leu) have been determined to be pathogenic (PMID: 20142534, 20883824, 21880868, 25914719). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="POLG" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.(?_89862161)_(89864158_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0205710" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7073372" TraitType="Disease" MappingType="XRef" MappingValue="C0205710" MappingRef="MedGen">
        <MedGen CUI="C0205710" Name="Progressive sclerosing poliodystrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

